L

Lumos Diagnostics Holdings Ltd
ASX:LDX

Watchlist Manager
Lumos Diagnostics Holdings Ltd
ASX:LDX
Watchlist
Price: 0.038 AUD 2.7% Market Closed
Market Cap: 28.4m AUD
Have any thoughts about
Lumos Diagnostics Holdings Ltd?
Write Note

Lumos Diagnostics Holdings Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lumos Diagnostics Holdings Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
L
Lumos Diagnostics Holdings Ltd
ASX:LDX
Total Current Assets
$9.6m
CAGR 3-Years
-45%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Total Current Assets
AU$198.4m
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
20%
Polynovo Ltd
ASX:PNV
Total Current Assets
AU$79.3m
CAGR 3-Years
70%
CAGR 5-Years
32%
CAGR 10-Years
30%
SDI Ltd
ASX:SDI
Total Current Assets
AU$64.7m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
7%
Anteris Technologies Ltd
ASX:AVR
Total Current Assets
AU$35.9m
CAGR 3-Years
64%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Ansell Ltd
ASX:ANN
Total Current Assets
$1.6B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
6%
No Stocks Found

Lumos Diagnostics Holdings Ltd
Glance View

Market Cap
28.4m AUD
Industry
Health Care

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care (POC) diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm's solutions help healthcare professionals to accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and digital reader platforms. The firm's portfolio of product, technology and service offerings include Point-of-care diagnostic products, Point-of-care readers, Commercial services and Manufacturing services. The firm's products include FebriDx and CoviDx. FebriDx is an all-in-one point-of-care test device that can differentiate a viral from bacterial acute respiratory infection. CoviDx is a rapid immunoassay for the detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

LDX Intrinsic Value
0.169 AUD
Undervaluation 78%
Intrinsic Value
Price
L

See Also

What is Lumos Diagnostics Holdings Ltd's Total Current Assets?
Total Current Assets
9.6m USD

Based on the financial report for Jun 30, 2024, Lumos Diagnostics Holdings Ltd's Total Current Assets amounts to 9.6m USD.

What is Lumos Diagnostics Holdings Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
16%

Over the last year, the Total Current Assets growth was 60%. The average annual Total Current Assets growth rates for Lumos Diagnostics Holdings Ltd have been -45% over the past three years , 16% over the past five years .

Back to Top